Abstract
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
Highlights
Rituximab therapy has been associated with more severe COVID-19 infection in persons with multiple sclerosis,[1,2] this finding was based on a small number of events
Of the 3391 persons who were enrolled in the COMBAT-MS cohort, 326 (9.6%) contracted COVID-19 infection during the study period
Among 172 Swedish persons with multiple sclerosis who received rituximab before contracting COVID-19, we found no statistically significant association between the timing of rituximab infusion or cumulative lifetime rituximab dose and the odds of hospitalization for COVID-19, the study power was limited
Summary
Rituximab therapy has been associated with more severe COVID-19 infection in persons with multiple sclerosis,[1,2] this finding was based on a small number of events. Further research is needed to evaluate the potential increased risk for severe disease. We examined the association between timing and dose of rituximab and hospitalization for COVID-19 across Sweden
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
